nach oben

Hepatology International

Erschienen in:

04.04.2018 | Editorial

Early occurrence and recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after sustained virological response

verfasst von: Tatsuo Kanda, Shunichi Matsuoka, Mitsuhiko Moriyama

Erschienen in: Hepatology International | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Excerpt

Chronic hepatitis C virus (HCV) infection is one of the major causes of liver cirrhosis and hepatocellular carcinoma (HCC). Recently, the interferon-free combination of direct-acting antiviral agents (DAAs) against HCV could result in higher sustained virological response (SVR) rates (~ 95%) [1]. In the interferon era, long-term eradication of HCV could lead to the reduction of liver-related complications, including HCC [2]. In the DAA era, achievement of SVR and long-term eradication of HCV can be expected to prevent liver-related complications, including HCC. …

Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 2016;10:702–726

Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409–435

Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051–1055

Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999;131:174–181

Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429–2441

Takayama T, Makuuchi M. Prevention of hepatocellular carcinoma recurrence: actuality and perspectives. Hepatogastroenterology 2002;49:87–90

Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299–306

Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;32:851–858

Huang JF, Yeh ML, Yu ML, Dai CY, Huang CF, Huang CI, et al. The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients. J Gastroenterol Hepatol 2015;30:1768–774

10.

Lee SH, Jin YJ, Shin JY, Lee JW. Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs. Medicine (Baltimore) 2017;96:e5321

11.

Nirei K, Kanda T, Nakamura H, Matsuoka S, Takayama T, Sugitani M, et al. Persistent hepatic inflammation plays a role in hepatocellular carcinoma after sustained virological response in patients with HCV infection. Int J Med Sci 2018;15:466–474

12.

Ryu T, Takami Y, Wada Y, Tateishi M, Matsushima H, Yoshitomi M, et al. Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation. Hepatol Int 2018. https://doi.org/10.1007/s12072-018-9851-4

13.

Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int 2010;4:548–561

14.

Kanda T. Interferon-free treatment for HCV-infected patients with decompensated cirrhosis. Hepatol Int 2017;11:38–44

15.

Kanda T, Imazeki F, Mikami S, Kato K, Shimada N, Yonemitsu Y, et al. Occurrence of hepatocellular carcinoma was not a rare event during and immediately after antiviral treatment in Japanese HCV-positive patients. Oncology 2011;80:366–372

16.

Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719–726

17.

Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017;153(996–1005):e1

18.

Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 2017;67:1204–1212

19.

Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 2017. https://doi.org/10.1016/j.jhep.2017.08.030 (Epub ahead of print)

20.

Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, et al. Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study. J Hepatol 2018. https://doi.org/10.1016/j.jhep.2018.03.009 (Epub ahead of print)

21.

Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, Lo Re V, et al. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study. Hepatology 2017. https://doi.org/10.1002/hep.29707 (Epub ahead of print)

22.

Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727–733

23.

Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology 2018. https://doi.org/10.1002/hep.29855 (Epub ahead of print)

24.

Teng W, Hsieh YC, Lui KW, Chen WT, Hung CF, Huang CH, et al. Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization. J Viral Hepat 2017;24:1160–1167

25.

Martin B, Hennecke N, Lohmann V, Kayser A, Neumann-Haefelin C, Kukolj G, et al. Restoration of HCV-specific CD8 + T cell function by interferon-free therapy. J Hepatol 2014;61:538–543

26.

Hengst J, Falk CS, Schlaphoff V, Deterding K, Manns MP, Cornberg M, et al. Direct-acting antiviral-induced hepatitis C virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C. J Infect Dis 2016;214:1965–1974

27.

Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, et al. Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget 2018;9:11631–11637

28.

Debes JD, van Tilborg M, Groothuismink ZMA, Hansen BE, Schulze Zur Wiesch J, von Felden J, et al. Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals. Gastroenterology 2018;154(515–517):e3

Titel: Early occurrence and recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after sustained virological response
verfasst von: Tatsuo Kanda
Shunichi Matsuoka
Mitsuhiko Moriyama
Publikationsdatum: 04.04.2018
Verlag: Springer India
Erschienen in: Hepatology International / Ausgabe 2/2018
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-018-9862-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Early occurrence and recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after sustained virological response

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Psychiatric comorbidities among patients undergoing liver transplantation in South Korea: a nationwide population-based study

Spontaneous bacteremia and spontaneous bacterial peritonitis in cirrhosis: two infections but similar outcomes?

Prevention of mother-to-child transmission: the key of hepatitis B virus elimination

Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment

Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B

Spectrum of histopathological changes in patients with non-cirrhotic portal fibrosis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin